HUBC has effectively acquired control of Evofem by issuing stock worth multiples of the company's current market cap. The pre-funded warrants, once the 4.99% caps are lifted (pending shareholder vote), could add ~30M shares to what is already a tiny float — a massive future overhang. Monitor for shareholder vote timing on warrant cap removal and any Nasdaq listing standard issues given the dramatic share count expansion.
Price Chart
Executive Summary
HUB Cyber Security acquired senior subordinated convertible notes and purchase rights of Evofem Biosciences (Evofem) for ~$49.3M, paid entirely in newly issued HUBC equity (1.79M ordinary shares + pre-funded warrants for 29.83M shares). The deal gives HUBC an 88% ownership stake in Evofem (14% fully diluted) and zero-cash entry into women's health, but massively dilutes existing HUBC shareholders. The filing also describes a broader restructuring with ~50% headcount reduction at HUB and engagement of Deloitte.
Key Facts
- Acquired Evofem convertible notes (~$5.37M principal) and purchase rights (~$10.15M) for ~$49.33M total, paid entirely in HUBC equity at $1.56/share (June 24 close)
- Issued 31,623,000 Consideration Shares: 1,794,901 ordinary shares + pre-funded warrants for 29,828,099 shares (exercise price $0.001)
- Pre-funded warrants limited to 4.99% beneficial ownership per holder; shareholder meeting required to lift cap and increase authorized capital
- Shares outstanding before issuance: 4,291,960. New issuance represents ~7.4x the pre-deal float in potential dilution
- Evofem notes and purchase rights convertible/exercisable into ~1.008 billion Evofem shares at $0.0154/share, giving HUBC 88% ownership (14% fully diluted)
- Company cut headcount ~50% at the HUB level, engaged Deloitte for restructuring, exploring strategic alternatives; no CEO since April 1, 2026
- Chair stated Evofem had 'north of $20 million in sales in 2025'; no HUBC financials provided in filing
- Market cap ~$6M; deal valued at 8x market cap in stock, severely dilutive to common shareholders
Financial Impact
HUBC issued 31,623,000 equity-linked shares in exchange for Evofem notes/purchase rights valued at $49.33M, against a pre-deal share count of ~4.29M. The pre-funded warrants (29.83M shares) remain subject to 4.99% beneficial ownership caps, but if shareholder approval lifts the caps, dilution from full warrant exercise would be enormous. HUBC's market cap of ~$6M implies the deal equity value exceeds the entire company.
Risk Factors
- Extreme dilution — 31.6M new shares vs 4.3M pre-deal outstanding; pre-funded warrants could add another ~30M shares
- No HUBC financials disclosed; company is undergoing restructuring with 50% headcount cuts and no CEO
- Evofem's convertibles are junior subordinated and Evofem trades OTC (EVFM), adding execution and integration risk
- Shareholder approval is required to lift the beneficial ownership cap on warrants; failure would leave warrants unexercisable at scale
- Nasdaq continued listing risk — market cap of only $6M, significant uncertainty about compliance
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-074019 |
| Document: ea029663001ex99-2.htm | 0001213900-26-074019 |
| Document: ea0296630-6k_hubcyber.htm | 0001213900-26-074019 |
| Document: ea029663001ex99-3.htm | 0001213900-26-074019 |
| Document: 0001213900-26-074019-index-headers.html | 0001213900-26-074019 |
| Document: 0001213900-26-074019-index.html | 0001213900-26-074019 |
| Document: 0001213900-26-074019.txt | 0001213900-26-074019 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 13d ago | 6-K | $0.3790 | awaiting T+20 | — | $0.1500 (−60.42%) |
Sep 28, 2026 28d ago | 6-K | $1.49 $0.1500 | ▲ +89.93% | ▲ +89.90% | $0.1500 (+89.93%) |
Aug 4, 2026 11w ago | 6-K | $1.03 | awaiting T+20 | — | $0.1500 (+85.44%) |
Aug 3, 2026 12w ago | 6-K | $1.04 $0.7375 | ▼ −29.09% | ▼ −30.32% | $0.1500 (−85.58%) |
Jul 17, 2026 14w ago | 20-F | $1.15 $0.7375 | ▲ +35.87% | ▲ +39.99% | $0.1500 (+86.96%) |
Jul 17, 2026 14w ago | Court Ruling | $1.15 $0.7375 | ▲ +35.87% | ▲ +39.99% | $0.1500 (+86.96%) |
Jul 1, 2026 16w ago | 6-K | $1.49 $1.03 | ▲ +30.87% | ▲ +30.33% | $0.1500 (+89.93%) |
Apr 16, 2026 27w ago | Press Release | $9.15 $0.1470 | ▼ −98.39% | ▼ −104.21% | $0.1500 (−98.36%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers